Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib + temozolomide in IDH-mutant glioma
2024-513738-39-00Phase 2Authorised
- Sponsor
- Servier
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of vorasidenib in glioma and IDH2-mutant glioma, sponsored by Servier. Primary endpoints: Dose-limiting toxicities (DLTs), Incidence and severity of adverse events (AEs) and 1 more. Planned start Feb 2025; status: authorised.
02
Drugs
vorasidenib
03
Conditions
gliomaIDH2-mutant glioma
Beyond the preview
Go deeper on 2024-513738-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513738-39-00.